ARS PHARMACEUTICALS INC

INSIDER confidence signals growth for ARS Pharmaceuticals: zero‑cost option buys, ImmunoTAC trials, and FDA milestones may drive future value.

RA Capital’s latest $8.54 strike option on ARS Pharmaceuticals shows a cautious but optimistic bet on the company’s future, balancing upside potential with limited downside risk.

Insider buying surge at ARS Pharmaceuticals signals long‑term confidence: 30k zero‑cost options hint at a future price rally despite current volatility.

INSIDER TRADING IN ARS PHARMACEUTICALS: CCO Eric Karas’ balanced buy‑sell strategy highlights short‑term gains and long‑term confidence in the ImmunoTAC platform, while market buzz and valuation cautions shape investor insight.